Publications by authors named "Qing Leng"
Article Synopsis
- The study assessed flumatinib for treating Chinese patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CP-CML) who previously failed tyrosine kinase inhibitors (TKIs).
- Among 336 patients, flumatinib showed high response rates, with 86.4% achieving complete hematologic response and significant cytogenetic and molecular responses, particularly in those without prior TKI resistance.
- Adverse events were manageable and similar to first-line therapies, suggesting flumatinib is a promising option for TKI-resistant or intolerant CP-CML patients, especially those without prior resistance to second-generation TKIs.
Objective: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely poor. This study prospectively observed the efficacy and safety of decitabine with a modified cisplatin, cytarabine, and dexamethasone (DHAP) regimen in R/R-DLBCL patients who failed second-line treatment.
Methods: Twenty-one R/R-DLBCL patients were enrolled and treated with decitabine and a modified DHAP regimen.